Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.68 |
| ▸ | JAK2 | O60674 | 18/20 | 0.68 |
| ▸ | JAK1 | P23458 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599293 | 1.00 | NTRK1 (0.68) | NTRK1JAK2JAK1 | |
| SCHEMBL20602710 | 0.93 | NTRK1 (0.66) | NTRK1JAK2JAK1 | |
| SCHEMBL21219502 | 0.93 | NTRK1 (0.66) | NTRK1JAK2JAK1 | |
| SCHEMBL20105989 | 0.92 | NTRK1 (0.61) | NTRK1JAK2JAK1 | |
| SCHEMBL20106508 | 0.92 | NTRK1 (0.61) | NTRK1JAK2JAK1 | |
| SCHEMBL30013959 | 0.92 | NTRK1 (0.61) | NTRK1JAK2JAK1 | |
| SCHEMBL20624671 | 0.87 | NTRK1 (0.58) | NTRK1JAK2JAK1 | |
| SCHEMBL2599272 | 0.85 | NTRK1 (0.70) | NTRK1JAK2JAK1 | |
| SCHEMBL2599268 | 0.85 | NTRK1 (0.70) | NTRK1JAK2JAK1 | |
| SCHEMBL932720 | 0.84 | NTRK1 (0.84) | NTRK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2020-09-17 | — | — | US | disclosed |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3521291-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-01-31 | — | — | US | disclosed |
| EP-3205654-B1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9902741-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9840519-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170283435-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9750744-B2 | Macrocyclic compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3205654-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170114059-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170107232-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-20 | — | — | US | disclosed |
| US-9493476-B2 | Macrocyclic compounds as trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150336970-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2918588-A1 | Macrocyclic compounds as TRK kinase inhibitors | Array Biopharma, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8933084-B2 | Macrocyclic compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2571883-B1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203776-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-08-08 | — | — | US | disclosed |
| EP-2571883-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146336-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203776-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 31/4885JAK2 127/4885JAK1 460/4885 |
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 31/4885JAK2 127/4885JAK1 460/4885 |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 27/4885JAK2 100/4885JAK1 417/4885 |
| US-20170283435-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 31/4885JAK2 127/4885JAK1 460/4885 |
| US-20150336970-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 23/4885JAK2 104/4885JAK1 468/4885 |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | MAP3K20, MAP3K1, MAP3K3 | NTRK1 27/4885JAK2 100/4885JAK1 417/4885 |
| US-20170107232-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 31/4885JAK2 127/4885JAK1 470/4885 |
| US-20170114059-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | NTRK1 31/4885JAK2 127/4885JAK1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.